Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Mult
- Written by PR Newswire
![]() |
– Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication –
NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...